Through phase 2. I don't expect they'll go through phase 3 without a partner.
I expect biodel to be required to run another trial, so that will delay. I don't consider Biodel serious competition unless they eliminate the injection site reactions it caused.
As I've said before unless a big partner buys in, i'm not sold on this being much bigger than a niche product.
Market Data 
Markets 
AI
